Literature DB >> 21583662

3-(2-Chloro-ethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.

Jerry P Jasinski, Ray J Butcher, Q N M Hakim Al-Arique, H S Yathirajan, B Narayana.   

Abstract

In the title mol-ecule, C(11)H(11)ClN(2)O, the pyrido[1,2-a]pyrimidine ring system is planar (maximum deviation = 0.0148 Å) and the methyl C and carbonyl O atoms are nearly coplanar to it. The chloro-ethyl side chain is in a synclinal conformation, nearly orthogonal to the pyrimidine ring, with a dihedral angle between the chloro-ethyl side chain and the pyrimidine ring of 88.5 (1)°. Weak inter-molecular C-H⋯N and C-H⋯Cl hydrogen bonds along with π-π inter-actions between the pyrimidine and pyridine rings [centroid-centroid distance is 3.538 (2) Å] form a three-dimensional network. The crystal is a racemic twin with a 0.68 (12):0.32 (12) domain ratio. MOPAC AM1 and density functional theory (DFT) theoretical calculations at the B3-LYP/6-311+G(d,p) level support these observations.

Entities:  

Year:  2009        PMID: 21583662      PMCID: PMC2977208          DOI: 10.1107/S1600536809027548

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For related structures, see: Blaton et al. (1995 ▶); Chen & He (2006 ▶); Elotmani et al. (2002 ▶); Jottier et al. (1992 ▶); Koval’chukova et al. (2004 ▶); Peeters et al. (1993 ▶); Ravikumar & Sridhar, (2006 ▶); Yu et al. (2007 ▶). For general background to heterofused pyrimidines, see: Baraldi et al. (2002 ▶); Bookser et al. (2005 ▶); Chen et al. (2004 ▶); La Motta et al. (2007 ▶); Gabbert & Giannini (1997 ▶); Goodacre et al. (2006 ▶); Hossain et al. (1997 ▶); Joseph & Burke (1993 ▶); Nikitin & Smirnov (1994 ▶); Sabnis & Rangnekar (1990 ▶); Wang et al. (2004 ▶); White et al. (2004 ▶). For the synthesis, see: Toche et al. (2008 ▶). For GAUSSIAN03 theoretical calculations, see: Becke (1988 ▶, 1993 ▶); Frisch et al. (2004 ▶); Hehre et al. (1986 ▶); Lee et al. (1988 ▶); Schmidt & Polik (2007 ▶).

Experimental

Crystal data

C11H11ClN2O M = 222.67 Orthorhombic, a = 4.2546 (4) Å b = 11.6274 (10) Å c = 20.604 (2) Å V = 1019.27 (17) Å3 Z = 4 Mo Kα radiation μ = 0.35 mm−1 T = 110 K 0.51 × 0.35 × 0.12 mm

Data collection

Oxford Diffraction Gemini R CCD diffractometer Absorption correction: multi-scan (CrysAlis RED; Oxford Diffraction, 2007 ▶) T min = 0.835, T max = 0.959 4613 measured reflections 3089 independent reflections 2607 reflections with I > 2σ(I) R int = 0.054

Refinement

R[F 2 > 2σ(F 2)] = 0.065 wR(F 2) = 0.181 S = 1.11 3089 reflections 138 parameters H-atom parameters constrained Δρmax = 0.99 e Å−3 Δρmin = −0.52 e Å−3 Absolute structure: Flack (1983 ▶), 1103 Friedel pairs Flack parameter: 0.32 (12) Data collection: CrysAlisPro (Oxford Diffraction, 2007 ▶); cell refinement: CrysAlisPro; data reduction: CrysAlisPro; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: SHELXTL (Sheldrick, 2008 ▶); software used to prepare material for publication: SHELXTL. Crystal structure: contains datablocks global, I. DOI: 10.1107/S1600536809027548/ci2827sup1.cif Structure factors: contains datablocks I. DOI: 10.1107/S1600536809027548/ci2827Isup2.hkl Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C11H11ClN2OF(000) = 464
Mr = 222.67Dx = 1.451 Mg m3
Orthorhombic, P212121Mo Kα radiation, λ = 0.71073 Å
Hall symbol: P 2ac 2abCell parameters from 2755 reflections
a = 4.2546 (4) Åθ = 4.8–32.6°
b = 11.6274 (10) ŵ = 0.35 mm1
c = 20.604 (2) ÅT = 110 K
V = 1019.27 (17) Å3Plate, colorless
Z = 40.51 × 0.35 × 0.12 mm
Oxford Diffraction Gemini R CCD diffractometer3089 independent reflections
Radiation source: Enhance (Mo) X-ray Source2607 reflections with I > 2σ(I)
graphiteRint = 0.054
Detector resolution: 10.5081 pixels mm-1θmax = 32.6°, θmin = 4.9°
φ and ω scansh = −3→6
Absorption correction: multi-scan (CrysAlis RED; Oxford Diffraction, 2007)k = −17→16
Tmin = 0.835, Tmax = 0.959l = −30→27
4613 measured reflections
Refinement on F2Secondary atom site location: difference Fourier map
Least-squares matrix: fullHydrogen site location: inferred from neighbouring sites
R[F2 > 2σ(F2)] = 0.065H-atom parameters constrained
wR(F2) = 0.181w = 1/[σ2(Fo2) + (0.1108P)2 + 0.2652P] where P = (Fo2 + 2Fc2)/3
S = 1.11(Δ/σ)max = 0.001
3089 reflectionsΔρmax = 0.99 e Å3
138 parametersΔρmin = −0.51 e Å3
0 restraintsAbsolute structure: Flack (1983), 1103 Friedel pairs
Primary atom site location: structure-invariant direct methodsFlack parameter: 0.32 (12)
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
Cl0.49448 (19)0.87358 (6)0.12093 (3)0.02056 (18)
O0.1937 (6)1.09071 (18)0.30555 (10)0.0240 (5)
N1−0.0403 (6)0.9961 (2)0.39118 (10)0.0150 (4)
N20.0097 (7)0.79306 (19)0.40322 (11)0.0172 (4)
C10.1541 (7)0.9982 (2)0.33357 (13)0.0151 (5)
C2−0.1616 (9)1.0994 (2)0.41318 (14)0.0207 (6)
H2A−0.11161.16850.39090.025*
C3−0.3506 (8)1.1032 (3)0.46596 (15)0.0231 (6)
H3A−0.43541.17440.48030.028*
C4−0.4212 (7)0.9999 (3)0.49970 (14)0.0211 (6)
H4A−0.55301.00190.53690.025*
C5−0.3006 (8)0.8986 (2)0.47886 (13)0.0191 (5)
H5A−0.34770.82990.50190.023*
C6−0.1033 (7)0.8935 (2)0.42262 (13)0.0147 (5)
C70.1973 (8)0.7917 (2)0.34977 (13)0.0155 (5)
C80.3087 (9)0.6735 (2)0.33069 (16)0.0239 (6)
H8A0.25810.61880.36530.036*
H8B0.53660.67500.32380.036*
H8C0.20380.64990.29050.036*
C90.2748 (7)0.8891 (2)0.31499 (12)0.0146 (5)
C100.4766 (9)0.8869 (2)0.25437 (12)0.0182 (5)
H10A0.62680.82200.25670.022*
H10B0.59830.95920.25110.022*
C110.2671 (7)0.8733 (3)0.19491 (13)0.0201 (5)
H11A0.11300.93710.19360.024*
H11B0.14890.80020.19820.024*
U11U22U33U12U13U23
Cl0.0233 (3)0.0253 (3)0.0132 (3)−0.0031 (3)0.0030 (3)−0.0001 (2)
O0.0323 (13)0.0185 (9)0.0214 (10)−0.0029 (9)0.0024 (10)0.0048 (8)
N10.0188 (11)0.0144 (8)0.0118 (9)0.0013 (9)−0.0009 (9)0.0005 (7)
N20.0200 (10)0.0157 (8)0.0160 (10)−0.0002 (12)−0.0001 (11)0.0019 (7)
C10.0168 (12)0.0163 (11)0.0122 (11)−0.0028 (11)−0.0005 (10)0.0002 (9)
C20.0286 (15)0.0163 (11)0.0173 (13)0.0039 (12)0.0000 (12)−0.0001 (9)
C30.0259 (15)0.0235 (13)0.0198 (14)0.0058 (13)−0.0013 (12)−0.0054 (10)
C40.0198 (14)0.0300 (14)0.0135 (12)0.0026 (12)0.0017 (10)−0.0019 (10)
C50.0196 (13)0.0234 (12)0.0142 (12)−0.0029 (12)0.0018 (11)0.0028 (10)
C60.0178 (11)0.0146 (11)0.0118 (11)−0.0013 (9)−0.0029 (9)0.0017 (8)
C70.0194 (13)0.0125 (10)0.0146 (11)0.0001 (11)−0.0022 (11)−0.0001 (9)
C80.0282 (16)0.0167 (11)0.0267 (15)0.0015 (13)0.0028 (14)−0.0022 (10)
C90.0133 (11)0.0183 (11)0.0124 (12)−0.0020 (10)−0.0004 (9)0.0005 (9)
C100.0164 (12)0.0245 (12)0.0138 (11)−0.0008 (13)0.0011 (10)0.0003 (9)
C110.0178 (12)0.0305 (13)0.0119 (11)−0.0035 (12)0.0019 (10)−0.0012 (11)
Cl—C111.805 (3)C5—C61.432 (4)
O—C11.232 (3)C5—H5A0.95
N1—C21.383 (4)C7—C91.381 (4)
N1—C61.384 (3)C7—C81.505 (4)
N1—C11.447 (3)C8—H8A0.98
N2—C61.325 (3)C8—H8B0.98
N2—C71.360 (4)C8—H8C0.98
C1—C91.421 (4)C9—C101.516 (4)
C2—C31.353 (5)C10—C111.523 (4)
C2—H2A0.95C10—H10A0.99
C3—C41.420 (5)C10—H10B0.99
C3—H3A0.95C11—H11A0.99
C4—C51.355 (4)C11—H11B0.99
C4—H4A0.95
C2—N1—C6121.5 (2)N2—C7—C8114.0 (2)
C2—N1—C1117.9 (2)C9—C7—C8122.6 (3)
C6—N1—C1120.6 (2)C7—C8—H8A109.5
C6—N2—C7117.9 (2)C7—C8—H8B109.5
O—C1—C9127.1 (3)H8A—C8—H8B109.5
O—C1—N1118.5 (3)C7—C8—H8C109.5
C9—C1—N1114.4 (2)H8A—C8—H8C109.5
C3—C2—N1120.9 (3)H8B—C8—H8C109.5
C3—C2—H2A119.5C7—C9—C1120.4 (2)
N1—C2—H2A119.5C7—C9—C10123.3 (2)
C2—C3—C4119.4 (3)C1—C9—C10116.3 (2)
C2—C3—H3A120.3C9—C10—C11109.5 (3)
C4—C3—H3A120.3C9—C10—H10A109.8
C5—C4—C3120.0 (3)C11—C10—H10A109.8
C5—C4—H4A120.0C9—C10—H10B109.8
C3—C4—H4A120.0C11—C10—H10B109.8
C4—C5—C6120.9 (3)H10A—C10—H10B108.2
C4—C5—H5A119.5C10—C11—Cl111.4 (2)
C6—C5—H5A119.5C10—C11—H11A109.3
N2—C6—N1123.3 (2)Cl—C11—H11A109.3
N2—C6—C5119.6 (2)C10—C11—H11B109.3
N1—C6—C5117.2 (2)Cl—C11—H11B109.3
N2—C7—C9123.4 (2)H11A—C11—H11B108.0
C2—N1—C1—O−2.5 (4)C4—C5—C6—N2−179.6 (3)
C6—N1—C1—O177.1 (3)C4—C5—C6—N10.5 (4)
C2—N1—C1—C9178.7 (3)C6—N2—C7—C9−0.1 (4)
C6—N1—C1—C9−1.8 (4)C6—N2—C7—C8−178.8 (3)
C6—N1—C2—C3−0.9 (5)N2—C7—C9—C1−1.0 (4)
C1—N1—C2—C3178.6 (3)C8—C7—C9—C1177.6 (3)
N1—C2—C3—C41.0 (5)N2—C7—C9—C10−178.2 (3)
C2—C3—C4—C5−0.3 (5)C8—C7—C9—C100.4 (5)
C3—C4—C5—C6−0.5 (5)O—C1—C9—C7−176.9 (3)
C7—N2—C6—N10.2 (4)N1—C1—C9—C71.8 (4)
C7—N2—C6—C5−179.7 (3)O—C1—C9—C100.6 (4)
C2—N1—C6—N2−179.7 (3)N1—C1—C9—C10179.3 (2)
C1—N1—C6—N20.8 (4)C7—C9—C10—C1190.7 (3)
C2—N1—C6—C50.2 (4)C1—C9—C10—C11−86.6 (3)
C1—N1—C6—C5−179.3 (3)C9—C10—C11—Cl178.6 (2)
D—H···AD—HH···AD···AD—H···A
C5—H5A···N2i0.952.503.394 (3)157
C2—H2A···Clii0.952.903.559 (3)128
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯AD—HH⋯ADAD—H⋯A
C5—H5A⋯N2i0.952.503.394 (3)157
C2—H2A⋯Clii0.952.903.559 (3)128

Symmetry codes: (i) ; (ii) .

  13 in total

1.  Clinical Therapeutic Conference: dopaminergic/serotonergic actions of phencyclidine as a model for schizophreniform psychosis.

Authors:  J F Gabbert; A J Giannini
Journal:  Am J Ther       Date:  1997-04       Impact factor: 2.688

2.  Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.

Authors:  Simon C Goodacre; Leslie J Street; David J Hallett; James M Crawforth; Sarah Kelly; Andrew P Owens; Wesley P Blackaby; Richard T Lewis; Joanna Stanley; Alison J Smith; Pushpinder Ferris; Bindi Sohal; Susan M Cook; Andrew Pike; Nicola Brown; Keith A Wafford; George Marshall; José L Castro; John R Atack
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

3.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density.

Authors: 
Journal:  Phys Rev B Condens Matter       Date:  1988-01-15

4.  Density-functional exchange-energy approximation with correct asymptotic behavior.

Authors: 
Journal:  Phys Rev A Gen Phys       Date:  1988-09-15

5.  Optimization of an anti-HIV hairpin ribozyme by in vitro selection.

Authors:  S Joseph; J M Burke
Journal:  J Biol Chem       Date:  1993-11-25       Impact factor: 5.157

6.  Synthesis and Antiviral Activity of the alpha-Analogues of 1,5-Anhydrohexitol Nucleosides (1,5-Anhydro-2,3-dideoxy-D-ribohexitol Nucleosides).

Authors:  Nafizal Hossain; Jef Rozenski; Erik De Clercq; Piet Herdewijn
Journal:  J Org Chem       Date:  1997-04-18       Impact factor: 4.354

7.  Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.

Authors:  Chen Chen; Keith M Wilcoxen; Charles Q Huang; Yun-Feng Xie; James R McCarthy; Thomas R Webb; Yun-Fei Zhu; John Saunders; Xin-Jun Liu; Ta-Kung Chen; Haig Bozigian; Dimitri E Grigoriadis
Journal:  J Med Chem       Date:  2004-09-09       Impact factor: 7.446

8.  Synthesis and anticonvulsant evaluation of some new 2-substituted-3-arylpyrido[2,3-d]pyrimidinones.

Authors:  David C White; Thomas D Greenwood; Aaron L Downey; Jeffrey R Bloomquist; James F Wolfe
Journal:  Bioorg Med Chem       Date:  2004-11-01       Impact factor: 3.641

9.  Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.

Authors:  Shouming Wang; Adrian Folkes; Irina Chuckowree; Xiaoling Cockcroft; Sukhjit Sohal; Warren Miller; John Milton; Stephen P Wren; Nigel Vicker; Paul Depledge; John Scott; Lyndsay Smith; Hazel Jones; Prakash Mistry; Richard Faint; Deanne Thompson; Simon Cocks
Journal:  J Med Chem       Date:  2004-03-11       Impact factor: 7.446

10.  Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity.

Authors:  Concettina La Motta; Stefania Sartini; Laura Mugnaini; Francesca Simorini; Sabrina Taliani; Silvia Salerno; Anna Maria Marini; Federico Da Settimo; Antonio Lavecchia; Ettore Novellino; Miriam Cantore; Paola Failli; Mario Ciuffi
Journal:  J Med Chem       Date:  2007-09-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.